Oct 6, 2026 07:48AM
Dec 23, 2025 06:46AM
Dec 16, 2025 12:18PM
Aug 6, 2025 07:00AM
Jul 28, 2025 08:31AM
Oct 8, 2024 08:05AM
Oct 8, 2024 08:05AM Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Aug 13, 2024 09:49AM
Jul 9, 2024 07:00AM
Jun 27, 2024 08:03AM
Jun 27, 2024 08:00AM
May 17, 2024 08:00AM
May 17, 2024 08:00AM
May 14, 2024 08:00AM Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 2, 2024 08:00AM
May 2, 2024 08:00AM
Apr 30, 2024 04:45AM
Apr 25, 2024 08:30AM
Apr 25, 2024 08:26AM
Mar 28, 2024 04:02PM
Mar 26, 2024 08:00AM Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Feb 20, 2024 08:15AM
Feb 20, 2024 08:00AM
Feb 6, 2024 08:00AM
Feb 6, 2024 08:00AM
Dec 26, 2023 11:54AM
Dec 26, 2023 08:30AM
Dec 26, 2023 08:30AM Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Nov 9, 2023 08:00AM
Nov 8, 2023 08:00AM
Oct 3, 2023 08:05AM
Oct 3, 2023 08:00AM
Aug 9, 2023 08:00AM
Jun 29, 2023 09:01AM
Jun 29, 2023 09:00AM Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
Nov 19, 2021 08:30AM
Nov 19, 2021 08:30AM
Mar 30, 2021 08:00AM
Feb 18, 2021 09:23AM

1,201,801 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All